Public Market Listing
4507TSE
Live quotes, historical charts, and market capitalization for Shionogi are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
7Total Assets
5Approved
2Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | HIV integraseSmall molecule | HIV |
| Approved | Reactive oxygen species (ROS)Small molecule | Amyotrophic Lateral Sclerosis | |
Elvitegravir(Stribild) | Approved | HIV integraseSmall molecule | HIV |
| Approved | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular DiseaseHomozygous Familial HypercholesterolemiaCardiovascular Disease / Dyslipidemia Hypertriglyceridemia | |
| Approved | Aryl hydrocarbon receptor · Aryl Hydrocarbon Receptor AgonistSmall molecule | Atopic DermatitisPsoriasis | |
| Phase 3 | CETPSmall molecule | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (5)
May 2027 (1)
Est. primary completion 2027-05-28 · NCT07619118 · CT.gov ↗
What to watch
July 2027 (1)
Est. primary completion 2027-07-30 · NCT07619131 · CT.gov ↗
What to watch
August 2027 (2)
October 2027 (1)
Est. primary completion 2027-10-11 · NCT07930507 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Est. primary completion 2032-09-14 · NCT07393659 · CT.gov ↗
What to watch
Financial reports
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $3.3B | $810M | $4.5B | — | report ↗ |